SCHEMBL196215

SCHEMBL196215

Cc1ccc2oc(-c3ccc4ccccc4c3O)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.56
RAB9A P51151 9/20 0.56
HPGD P15428 8/20 0.56
NPC1 O15118 8/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
CASP3 P42574 4/20 0.56
SENP7 Q9BQF6 4/20 0.56
SENP6 Q9GZR1 4/20 0.56
SENP8 Q96LD8 3/20 0.56
POLB P06746 2/20 0.56
ALDH1A1 P00352 9/20 0.51
HSD17B10 Q99714 6/20 0.51
TP53 P04637 3/20 0.51
MAPT P10636 7/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ESR1 P03372 4/20 0.48
ESR2 Q92731 4/20 0.48
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18086820 0.90 RPS6KA3 (0.57) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL30498604 0.86 KDM4E (0.69) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL13620844 0.86 KDM4E (0.69) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL18086821 0.85 ESR1 (0.51) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL30487873 0.85 KDM4E (0.57) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL25246874 0.83 ALDH1A1 (0.70) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL196237 0.83 KDM6B (0.54) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL13620843 0.82 KDM4E (0.63) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL1549307 0.82 HPGD (0.56) KDM4ERAB9AHPGDNPC1SMN1; SMN2
SCHEMBL2244464 0.80 UTRN (0.64) KDM4ERAB9AHPGDNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221770-B2 Compounds having electron transport properties, their preparation and use MERCK PATENT GMBH (DE) 2015-12-29 US claimed
JP-2012500235-A 2012-01-05 JP claimed
US-20110108819-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE MERCK PATENT GMBH (DE) 2011-05-12 US claimed
EP-2313383-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE Merck Patent GmbH (DE) 2011-04-27 EP claimed
WO-2010020352-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE MERCK PATENT GMBH (DE) 2010-02-25 WO claimed
US-9221770-B2 Compounds having electron transport properties, their preparation and use MERCK PATENT GMBH (DE) 2015-12-29 US disclosed
US-9221770-B2 Compounds having electron transport properties, their preparation and use MERCK PATENT GMBH (DE) 2015-12-29 US disclosed
US-9221770-B2 Compounds having electron transport properties, their preparation and use MERCK PATENT GMBH (DE) 2015-12-29 US disclosed
US-20110108819-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE MERCK PATENT GMBH (DE) 2011-05-12 US disclosed
US-20110108819-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE MERCK PATENT GMBH (DE) 2011-05-12 US disclosed
US-20110108819-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE MERCK PATENT GMBH (DE) 2011-05-12 US disclosed
EP-2313383-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE Merck Patent GmbH (DE) 2011-04-27 EP disclosed
WO-2010020352-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE MERCK PATENT GMBH (DE) 2010-02-25 WO disclosed
WO-2010020352-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE MERCK PATENT GMBH (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110108819-A1 COMPOUNDS HAVING ELECTRON TRANSPORT PROPERTIES, THEIR PREPARATION AND USE SLC25A21, SLCO4C1, SLCO1B3 KDM4E 4607/4885RAB9A 1290/4885HPGD 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.